Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bora Gurel

Showing results (31-40 of 79) with videos related to

Pageof 8
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 22, 2014
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trialBora Gurel, M Scott Lucia, Ian M Thompson, et al.
Journal for Immunotherapy of Cancer|July 26, 2024
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapyHaider Al-Janabi, Katy Moyes, Richard Allen, et al.
Science Translational Medicine|June 30, 2012
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapySamuel R Denmeade, Annastasiah M Mhaka, D Marc Rosen, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2012
Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcomePaula J Hurley, Luigi Marchionni, Brian W Simons, et al.
European Urology|October 21, 2018
Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair DeficiencyZafeiris Zafeiriou, Diletta Bianchini, Robert Chandler, et al.
European Urology Open Science|June 7, 2023
Germline <i>ATM</i> Mutations Detected by Somatic DNA Sequencing in Lethal Prostate CancerRafael Grochot, Suzanne Carreira, Susana Miranda, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 31, 2015
Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention TrialTeemu J Murtola, Bora Gurel, Martin Umbehr, et al.
Journal for Immunotherapy of Cancer|March 15, 2020
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumabAnna Minchom, Wei Yuan, Mateus Crespo, et al.
European Urology|July 27, 2019
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate CancerAlec Paschalis, Beshara Sheehan, Ruth Riisnaes, et al.
European Urology|March 8, 2021
CD38 in Advanced Prostate CancersChristina Guo, Mateus Crespo, Bora Gurel, et al.
Pageof 8

Showing results (31-40 of 79) with videos related to

Sort By:
Pageof 8
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 22, 2014
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trialBora Gurel, M Scott Lucia, Ian M Thompson, et al.
Journal for Immunotherapy of Cancer|July 26, 2024
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapyHaider Al-Janabi, Katy Moyes, Richard Allen, et al.
Science Translational Medicine|June 30, 2012
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapySamuel R Denmeade, Annastasiah M Mhaka, D Marc Rosen, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2012
Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcomePaula J Hurley, Luigi Marchionni, Brian W Simons, et al.
European Urology|October 21, 2018
Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair DeficiencyZafeiris Zafeiriou, Diletta Bianchini, Robert Chandler, et al.
European Urology Open Science|June 7, 2023
Germline <i>ATM</i> Mutations Detected by Somatic DNA Sequencing in Lethal Prostate CancerRafael Grochot, Suzanne Carreira, Susana Miranda, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 31, 2015
Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention TrialTeemu J Murtola, Bora Gurel, Martin Umbehr, et al.
Journal for Immunotherapy of Cancer|March 15, 2020
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumabAnna Minchom, Wei Yuan, Mateus Crespo, et al.
European Urology|July 27, 2019
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate CancerAlec Paschalis, Beshara Sheehan, Ruth Riisnaes, et al.
European Urology|March 8, 2021
CD38 in Advanced Prostate CancersChristina Guo, Mateus Crespo, Bora Gurel, et al.
Pageof 8